Comparative Pharmacology
Head-to-head clinical analysis: STERI STAT versus UCERIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STERI STAT versus UCERIS.
STERI-STAT vs UCERIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by blocking peptide bond formation and translocation.
Uceris (budesonide) is a corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines (e.g., IL-1, IL-2, IL-4, IL-5, TNF-alpha), suppression of arachidonic acid metabolism via phospholipase A2 inhibition, and reduction of inflammatory cell infiltration. It has high topical anti-inflammatory activity and undergoes extensive first-pass hepatic metabolism, minimizing systemic bioavailability.
Adults: 1 gram intravenously every 8 hours infused over 60 minutes.
For induction of remission in mild to moderate active ulcerative colitis: one 9 mg extended-release tablet orally once daily for up to 8 weeks.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
2.8-4.5 hours (terminal). Clinical context: short half-life supports once-daily extended-release formulation for colonic delivery.
Renal excretion of unchanged drug accounts for approximately 95% of elimination; biliary/fecal elimination is minimal (<5%).
Renal: <1%. Fecal: approximately 63% as budesonide and metabolites. Biliary: minor.
Category C
Category C
Corticosteroid
Corticosteroid